Coronary disease & ACSCohort study

Pharmacological treatment after a first myocardial infarction in Sweden—long-term adherence and prognosis

Eur Heart J Qual Care Clin OutcomesPublished

  • Time-updated survival analyses of a national register cohort
  • Swedish National Inpatient Register linked to the Prescribed Drug Register

Authors' conclusion

The use of all GDMT is associated with lower risk for all-cause mortality and recurrent myocardial infarction. Long-term adherence of GDMT is suboptimal and there is a potential for further improvement.

Study context

Population
Patients aged 18–84 years hospitalized with a first acute myocardial infarction (MI) between 2006 and 2022 in Swedenindividuals with acute MI (29.3% women)
Participants
96,272 patients
Exposure
Relationship between guideline-directed medical therapy (GDMT) and mortality and/or recurrent MI

Main finding

As reported in the abstract

Use of GDMT · first year after MI
  • Use of GDMT decreased markedly

Observational data: associations, not effects.

Further findings

All-cause mortality or recurrent MI

ComparisonHR (95% CI)P value
antiplatelet/OAC · lower risk; all P < 0.0001 · time-updated survival analyses0.76 (0.74–0.78)P < 0.0001
lipid lowering therapy · lower risk; all P < 0.0001 · time-updated survival analyses0.68 (0.67–0.70)P < 0.0001
ACEi/ARB · lower risk; all P < 0.0001 · time-updated survival analyses0.81 (0.79–0.83)P < 0.0001

All-cause mortality or recurrent MI, beta-blockers

ComparisonHR (95% CI)P value
beta-blockers · slightly increased risk1.04 (1.02–1.07)P = 0.0005

Death · median follow-up of 5.6 years

Died
32.9%

Baseline characteristics

hypertension
48.4%
diabetes mellitus
18.8%
heart failure
13.5%

Original publication

Pharmacological treatment after a first myocardial infarction in Sweden—long-term adherence and prognosis. Eur Heart J Qual Care Clin Outcomes. Published 26 March 2026. doi:10.1093/ehjqcco/qcag050

Summarised from the published abstract; every number is checked against it